C - Chemistry – Metallurgy – 07 – H
Patent
C - Chemistry, Metallurgy
07
H
C07H 21/04 (2006.01) C12N 15/00 (2006.01) C12Q 1/68 (2006.01)
Patent
CA 2566823
Patients with ErB2-overxprsessing cancers can be given an ErB2 targeting agent as a therapeutic regimen but not all patients are responsive. The present invention concerns the diagnostic, prognostic and therapeutic methods and compositions for evaluating potential efficacy of an ErB2 targeting agent in an ErB2-overxpressing cancers by evaluating PTEN expression, which is predictive of responsiveness or resistance to ErB2 targeting agents such as trastuzumab. Low PTEN expression is predictive of a patient who will respond poorly to trastuzumab.
L'invention concerne un agent cible de l'ErB2 administré à des patients souffrant de cancers à surexpression de l'ErB2, en tant que régime thérapeutique, tous les patients n'étant pas sensible audit agent cible. L'invention concerne des méthodes diagnostiques, pronostiques et thérapeutiques ainsi que des compositions pour évaluer l'efficacité potentielle d'un agent cible de l'ErB2 dans des cancers à surexpression de l'ErB2 grâce à l'évaluation de l'expression de PTEN, qui prévoit la responsabilité ou la résistance aux agents cibles de l'ErB2 tels que le trastuzumab. Une expression faible de PTEN est prévue pour un patient peu sensible au trastuzumab.
Esteva Francisco J.
Nagata Yoichi
Sahin Aysegul A.
Yu Dihua
Zhou Xiaoyan
Bereskin & Parr Llp/s.e.n.c.r.l.,s.r.l.
Board Of Regents The University Of Texas System
LandOfFree
Diagnostic and therapeutic methods and compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Diagnostic and therapeutic methods and compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic and therapeutic methods and compositions... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-2030434